Printer Friendly

STRYKER'S BONE-GROWTH DEVICE APPROVED FOR CLINICAL STUDIES

       STRYKER'S BONE-GROWTH DEVICE APPROVED FOR CLINICAL STUDIES
    KALAMAZOO, Mich., Nov. 18 /PRNewswire/ -- Stryker Corporation (NASDAQ-NMS: STRY) and Creative BioMolecules, Inc. announced today that an approval has been received from the Food and Drug Administration (FDA) for an Investigation Device Exemption (IDE) to begin human clinical trials of Stryker's Osteogenic Protein Device.  This bone- growth device is comprised of a human recombinant osteogenic protein (OP-1) and a bioresorbable carrier to provide a scaffold for bone growth.  OP-1 has been developed by Creative BioMolecules, Inc. as a result of an extensive research and development program funded by Stryker Corporation.  In pre-clinical studies, the Osteogenic Protein Device has induced the formation of new bone when implanted into bone defect sites.  The human clinical studies will compare the efficacy of the Osteogenic Protein Device to autografts in the repair of non-union fractures.  The first human implants are expected in January 1992.
    Creative BioMolecules, Inc. is a privately held biopharmaceutical company focused on the discovery and development of a new class of protein-based therapeutics for the repair and regeneration of human tissues.  The company is based in Hopkinton, Mass.
    Stryker Corporation develops, manufactures and markets specialty surgical and medical products, including orthopedic implants, powered surgical instruments, endoscopic systems and patient-handling equipment for the world market.  Its shares are traded in the over-the-counter market on the NASDAQ National Market System under the symbol STRY.
    -0-                        11/18/91
    /CONTACT:  David J. Simpson of Stryker Corporation, 616-385-2600; or Charles M. Cohen, Ph.D., of Creative BioMolecules, Inc., 508-435-9001/
    (STRY) CO:  Stryker Corporation; Creative BioMolecules, Inc. ST:  Michigan, Massachusetts IN:  MTC SU:  PDT ML -- DE004 -- 1265 11/18/91 09:16 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 18, 1991
Words:274
Previous Article:ROHM AND HAAS TO ACQUIRE UNOCAL'S POLYMERS BUSINESS
Next Article:PEPSI-COLA TO DISTRIBUTE OCEAN SPRAY JUICES
Topics:


Related Articles
CREATIVE BIOMOLECULES AND STRYKER EXTEND OP-1 DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
GENETICS INSTITUTE, STRYKER AND CREATIVE BIOMOLECULES CROSS-LICENSE KEY BMP/OP PATENTS
CREATIVE BIOMOLECULES, STRYKER AND GENETICS INSTITUTE CROSS-LICENSE KEY BMP/OP PATENTS
Creative BioMolecules Reports First Quarter Results and Development Progress
Creative BioMolecules Sells OP-1 Manufacturing to Stryker.
Stryker Acquires OP-1 Manufacturing From Creative BioMolecules.
Creative BioMolecules, Inc. Reports Third Quarter Results.
Creative BioMolecules Closes OP-1 Manufacturing Sale to Stryker.
Creative BioMolecules Reports 1998 Year End Results.
North American Distribution Agreement for Inion OTPS Biodegradable Implants Signed Between Stryker Corporation and Inion.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters